See more : Shenzhen MinDe Electronics Technology Ltd. (300656.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SiriusPoint Ltd. (SPNT) Income Statement Analysis – Financial Results
- TISCO Financial Group Public Company Limited (TISCO-R.BK) Income Statement Analysis – Financial Results
- Navya SA (NAVYA.PA) Income Statement Analysis – Financial Results
- NHN Corporation (181710.KS) Income Statement Analysis – Financial Results
- BTS Group Holdings Public Company Limited (BTS.BK) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board
TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with...
Mindset Pharma says new study data indicates MSP-1014 is safer and more effective than generic psilocybin in treating neuropsychiatric disorders
Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) revealed positive new study data on its psychedelic compound MSP-1014. The drug discovery company said MSP-1014 demonstrated “superior efficacy” and an improved safety profile compared to generic psilocybin in a head-to-head clinical trial.
Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014
MSP-1014, a next generation psychedelic medicine showed superior 5-HT2A receptor efficacy and safety compared to psilocybin MSP-1014, a next generation psychedelic medicine showed superior 5-HT2A receptor efficacy and safety compared to psilocybin
Maxim Group initiates coverage of Mindset Pharma with a 'Buy' rating and price target of US$1
Maxim Group has initiated coverage of Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) with a "Buy" rating and a 12-month price target of US$1. Mindset Pharma is focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Mindset Pharma says InterVivo releases first data set for jointly developed Cooperative Psychedelics Evaluation Platform program
Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF), a biotechnology company developing psychedelic medicines and technologies, noted that InterVivo Solutions (IVS) had released the first data set as part of its jointly developed advanced Cooperative Psychedelics Evaluation Platform (COPE) program. The program,...
Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Dow pulls to above the flatline after morning struggles as traders digest jobs data
12:30pm: Nasdaq finds little upward momentum The Dow clawed its way out of an early deficit to 15 points higher at midday at 34,615. The Nasdaq was down 117 points, 0.9%, at 13,641, and the S&P 500 shed 12 points,...
Mindset Pharma selects next-generation psychedelic compound MSP-1014 as its lead clinical candidate
Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) has selected next-generation psychedelic compound MSP-1014 as its lead clinical candidate. In a statement, the company said the differentiated psilocybin-based compound will move forward into current good manufacturing practice (cGMP) compliant manufacturing and investigational new...
Mindset Pharma Invited to Present at Canaccord Genuity 41st Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - May 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has been invited to present at the Canaccord Genuity 41st Annual Growth Conference...
Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds
Toronto, Ontario--(Newsfile Corp. - April 29, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that certain of Mindset's Family 4 compounds, a group of patent-pending novel chemical entities that...
Source: https://incomestatements.info
Category: Stock Reports